February 22, 2024

The American Society of Clinical Oncology (ASCO) released a policy statement highlighting the top policy changes necessary to advance health equity in cancer care. The statement, published in JCO Oncology Practice, examines how social determinants of health (SDOH) can impact a patient’s access to cancer care and outcomes.

February 6, 2024

Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer & Executive Vice President of the Association for Clinical Oncology (ASCO), will testify before the full House Committee on Ways and Means on the crisis of ongoing cancer drug shortages. Dr. Gralow will share ASCO members’ firsthand experiences managing clinical care in the face of severe shortages. She will also urge Congress to take action to help mitigate the problem.

February 5, 2024

In a head-to-head study, the triplet therapy of belantamab mafodotin (belamaf) plus bortezomib, and dexamethasone (BVd) demonstrated a significantly improved progression-free survival compared to the current standard of care in patients with relapsed or refractory multiple myeloma. These results will be presented during the February 2024 session of the American Society of Clinical Oncology (ASCO) Plenary Series.

February 5, 2024

Results from a new phase 3 study conducted in China demonstrated a significant improvement in progression-free survival in patients with advanced stomach cancers. According to the authors, this is the first phase 3 trial to demonstrate survival benefits with a new treatment alternative to ramucirumab-containing therapy in the second-line setting for patients with advanced gastric or gastroesophageal junction adenocarcinoma. These results will be presented during the February 2024 session of the American Society of Clinical Oncology (ASCO) Plenary Series.

January 30, 2024

ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) announces the upcoming launch of JCO Oncology Advances (JCO OA), a new open-access and interdisciplinary journal. We are excited to name Pamela Kunz, MD, as the new Editor-in-Chief of this innovative journal dedicated to accelerating progress in the global fight against cancer by providing a platform where innovation in cancer research meets accessibility.  

January 27, 2024

The phase 3 KEYNOTE-564 study has reported that adjuvant pembrolizumab provides a significant improvement in overall survival for patients with clear cell renal cell carcinoma (ccRCC) at high risk of recurrence after surgery. This study is significant as it represents the first phase 3 study to show improved overall survival with any adjuvant therapy in kidney cancer. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27 in San Francisco, California. 

January 23, 2024

ALEXANDRIA, Va. — A new study published in the Journal of Clinical Oncology, conducted as part of the St. Jude Lifetime Cohort (SJLIFE), provides new insights into how diet affects aging in adult survivors of childhood cancer. This study, involving 3,322 participants between the ages of 18 and 65, found that higher consumption of dark green vegetables and nuts/seeds is associated with a lower risk of premature aging, while an increased intake of refined grains is linked to a higher risk. These findings, derived from assessments using the Deficit Accumulation Index (DAI), contribute to the growing understanding of the impact of specific dietary choices on the long-term health of childhood cancer survivors. This study is pivotal in understanding the importance of specific plant-based dietary choices in managing long-term health outcomes and enhancing the quality of life for childhood cancer survivors. 

January 22, 2024

Patients with metastatic castration-resistant prostate cancer (mCRPC) with extrapelvic nodal or visceral metastasis who were treated with the combination therapy of cabozantinib plus atezolizumab had significantly improved time to disease progression compared to those who were treated with hormonal therapy. This research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27 in San Francisco, California.

January 20, 2024

The dual immunotherapy combination of nivolumab and ipilimumab reduced the risk of disease progression or death by 79% compared to chemotherapy with or without targeted therapies as first-line treatment in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California.  

January 20, 2024

Ten studies exploring new approaches for the treatment of gastrointestinal cancers will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place in San Francisco, CA, and online, January 18-20. 

January 19, 2024

The addition of durvalumab and bevacizumab to TACE significantly improved progression-free survival in patients with unresectable hepatocellular carcinoma (uHCC) that were eligible for embolization. According to the authors, this is the first trial to demonstrate improved clinical outcomes for immunotherapy-based combinations with TACE in these patients. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California and online.

January 19, 2024

Results from the first phase 3 clinical trial evaluating radioligand therapy in the first-line setting demonstrated that treatment with [177Lu]Lu-DOTA-TATE significantly improved progression-free survival and objective response rates in patients with high-grade gastroenteropancreatic neuroendocrine tumors, potentially establishing a new standard of care. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California. 

January 17, 2024

The Centers for Medicare & Medicaid Services (CMS) issued its rule requiring federal health plans—including Medicare Advantage plans, Medicaid plans, and Qualified Health Plans (QHP) on Federally Facilitated Exchanges (FFEs)— to establish an electronic prior authorization process that will be integrated into providers’ workflows.

January 16, 2024

Results from a new phase III study found that combining PD-L1and TIGIT inhibitors plus chemotherapy in the first-line setting prolongs survival in an Asian population of patients with metastatic or locally advanced esophageal squamous cell carcinoma. This treatment combination has the potential to boost the body's ability to fight cancer and may ultimately lead to better outcomes for these patients with esophageal squamous cell carcinoma that cannot be surgically removed or has spread to other parts of the body. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California. 

January 16, 2024

The role of ctDNA, or liquid biopsy, as a predictive tool to guide and monitor cancer treatment, remains unclear after the first prospective randomized phase II trial evaluating clearance of ctDNA as a primary endpoint using adjuvant chemotherapy in patients with stage II colon cancer did not meet its endpoint. The NRG-GI005 (COBRA) phase II/III study was halted after the results of the pre-planned phase II analysis found that the use of chemotherapy did not increase the rate of ctDNA clearance among patients who had detectable ctDNA after surgery when compared to patients who did not receive chemotherapy. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California and online.

Pages